Despite obstacles and setbacks, these researchers vowed to never give up develop new treatment for non-small cell lung cancer
It’s a sobering fact: More people in the United States than any other type of cancer.
Lung cancer is often, after the disease has metastasised – in other words, spread to other parts of the body. At this advanced phase, therapies aren’t considered to be a cure, and the goal is to extend patients’ lives and quality of life as much as possible.
This is particularly true in the case of(NSCLC), which accounts for around . There are several types of NSCLC, and patients typically have a poor prognosis: for NSCLC with epidermal growth factor receptor (EGFR) mutations, the five-year survival rate is .
Initially, chemotherapy was the only treatment available. It provided short-lived anti-tumour activity and was significantly toxic. Over time, other types of treatments called tyrosine kinase inhibitors (TKIs) were found to improve patients’ lives and quality of life, but tumours developed resistance to these TKIs and patients had few options left.
It’s patients like these that spurred researchers at the Janssen Pharmaceutical Companies of Johnson & Johnson nearly 10 years ago to try and find an effective drug for EGFR mutant NSCLC. The team elected for a novel approach: a bispecific antibody, which is a recombinant protein that can bind to two different(substances that provoke an immune response in the body) that would target the disease.
It wasn’t an easy road—studies were delayed, the science was complex and thepandemic brought in-person work to a grinding halt. But now that the treatment has been approved by the US Food and Drug Administration (FDA), the team can proudly say their work and commitment have paid off.
“This is an exceptionally talented and dedicated team of drug developers,” says Amy Roshak, Vice President, Development and Oncology Portfolio and Lung Cancer Compound Development Team Leader at Janssen Research & Development, LLC.
“Their drive and commitment were endless. It’s really a privilege to work beside this team every day.”
We caught up with four scientists who were integral to the development of a treatment for NSCLC to learn exactly what it took.
Optimism and grit
In April 2013, Sheri Moores, Scientific Director, Oncology Discovery, Janssen R&D and her team were among the first to study the molecule that would become a new treatment for NSCLC. Normally, early experiments on a molecule take years, but in this case the initial results were so promising that the team reached the internal new molecular entity (NME) milestone, indicating that the molecule was ready for clinical development stage, in December of that year.
While she was excited by the drug’s potential, Dr Moores knew to be cautious. “You have to have a lot of optimism and grit when you work in drug discovery,” Dr Moores says.
“So many molecules seem promising in preclinical studies but fail for one reason or another in clinical trials.”
That grit came in handy later that year, when Janssen R&D had to put further studies of the molecule on hold after numerous other NMEs were declared at the company and priorities were reallocated. Though she was disappointed, Dr Moores was determined to find a way to keep the drug moving forward.
“The drug had so much potential that we refused to give up on it,” she says.
Dr Moores and her team decided that they would continue preclinical studies themselves the following year, hoping to increase the data package that would support testing the molecule in clinical trials.
Thanks to their extra effort, the molecule was handed to the WAVE programme, an early development unit at Janssen R&D that can run small clinical trials.
To see the drug attain FDA approval this month has been particularly special for Dr Moores.
“This is the first drug I’ve worked on that made it all the way to approval,” she says. “I always wanted to have an impact on patients’ lives, so the experience has been so rewarding.”
Although Dr Moores’ work had revealed that the drug had potential, Dr Nahor Haddish-Berhane, Scientific Director, Janssen R&D was also cautious about getting his hopes up. “Why would this bispecific antibody work so well when other EGFR antibodies that also had compelling data failed in this disease?” he thought at the time.
Passion for the job
Dr Haddish-Berhane joined the effort in late 2016, after the drug had shown promising results in clinical trials in South Korea. His team was tasked with determining the optimal dose. Unlike chemotherapy, this drug is a targeted treatment, which requires multiple strategies for determining the optimal dose, making the process more challenging.
“The drug was showing promising activity, but as we began enrolling more patients, we quickly needed to identify a dose that delivered the most benefits with the fewest side effects,” Dr Haddish-Berhane says.
He credits the recent FDA approval to the tireless efforts of his fellow scientists and the urgency they felt to deliver a targeted treatment to a group of patients who had so few options.
Dr Haddish-Berhane says his passion for his job comes from knowing how many people have lost loved ones to cancer. “I recently buried a beloved sister who lost the battle to gastric cancer,” he says.
“Such loss intensifies my passion to find, cure or even eradicate cancer.”
It’s a passion that has been ignited on the long road to developing this treatment. “Every time I see the scans from patients with tumour reductions, every time I hear the patient testimonials from the investigators involved in the clinical studies … those are the moments that make me realize what an important job this is.”
Once the optimal dose of the treatment had been identified, researchers faced another hurdle: producing enough of the drug to accommodate the increasing number of patients enrolled in the clinical trials.
This was in 2017, when the drug exited the WAVE programme and returned to theteam—the first drug ever to make the transition from WAVE to full-scale development midstream. This meant that scientists could expand the trials to include more patients in more locations.
It was Dr Francis Meacle, CMC Leader of Large Molecule Biologics, Janssen R&D who, with his team, would identify how the drug should be manufactured. While they had been able to produce a small amount of the drug for patients in earlier trials, ramping up manufacturing was daunting.
“These molecules, which are called bispecific antibodies, are much harder to make than Janssen’s current antibodies products,” he said. “It requires twice the amount of work, since two regular antibodies must be manufactured first and then combined together using a novel process to produce one bispecific antibody.”
Breakthrough therapy designation
But the long hours they put in paid off. Thanks to Dr Meacle and his team’s efforts, clinical trials were able to expand from two sites in South Korea to 80 sites in 11 countries. More than 800 patients would be enrolled in the trials—a huge jump from the initial target enrolment of 40 to 50 patients.
“To finally have a targeted treatment that can potentially help these patients has been very satisfying,” says Dr Meacle.
In March 2020, the drug was granteddesignation from the FDA—a step that would expedite development. But then an obstacle presented itself almost immediately after that: the Covid-19 pandemic. The team would have to finish the rest of the work required for the drug’s approval remotely.
“The ability of the team to collect and deliver data from the studies when they couldn’t even meet in person and when hospitals were under pressure was incredible,” says Dr Roland Knoblauch, Executive Medical Director, Clinical Oncology, Janssen R&D, who, as clinical leader, has overseen the development of the drug starting with the Phase 1 study.
And the work hasn’t ended yet. Janssen has submitted applications for approval of the drug in Europe, and global submissions are underway. The company is also studying it as part of a combination therapy.
Dr Knoblauch is hopeful that the drug will prove to be an effective treatment for other types of cancer, as well.
“There are several other types of tumors we can explore where one of the same genes that our bispecific binds to is overexpressed. I’m looking forward to seeing if there is potential for this drug to help patients with other types of cancers, too.” — The Health
This article appeared in May on the website of Johnson & Johnson